AUC

:   area under the curve

EMT

:   epithelial mesenchymal transition

FCs

:   fold changes

GEO

:   gene expression omnibus

HCC

:   hepatocellular carcinoma

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

miRs

:   microRNAs

NLP

:   natural language processing

ROC

:   receiver operator characteristic

TCGA

:   The Cancer Genome Atlas

Hepatocellular carcinoma (HCC) is considered to be the fifth most frequent cancer globally and takes the third place for cancer‐related mortality [1](#feb412198-bib-0001){ref-type="ref"}, [2](#feb412198-bib-0002){ref-type="ref"}. However, many patients are diagnosed at advanced stages, and recurrence and metastasis remain the main challenge for HCC treatment [3](#feb412198-bib-0003){ref-type="ref"}. Therefore, it is of utmost urgency to find novel diagnostic and prognostic biomarkers for HCC.

MicroRNAs (miRs) are an ample variety of short, noncoding RNA molecules of 18--25 nucleotides, which mediate numerous cellular processes, such as cell proliferation, migration, and apoptosis [4](#feb412198-bib-0004){ref-type="ref"}, [5](#feb412198-bib-0005){ref-type="ref"}. Among them is miR‐146a‐5p, which locates on human chromosome 5q34 and is thought to be actively involved in multiple oncological processes of HCC, such as antitumor immune suppression [6](#feb412198-bib-0006){ref-type="ref"}, metastasis [7](#feb412198-bib-0007){ref-type="ref"}, and angiogenesis [8](#feb412198-bib-0008){ref-type="ref"}. Our previous work [9](#feb412198-bib-0009){ref-type="ref"} has demonstrated that the down‐regulated miR‐146a‐5p expression is associated with the carcinogenesis and deterioration of HCC and that miR‐146a‐5p might be a tumor‐suppressive microRNA of HCC. Nevertheless, the precise molecular mechanisms of miR‐146a‐5p in HCC remain largely unknown and obscure.

Believed to be promising in cancer diagnostics and prognosis predicting, gene signatures help to provide the molecular backgrounds, regulatory pathways, and networks of cellular activities in HCC [10](#feb412198-bib-0010){ref-type="ref"}. Cases in point are resources and techniques as follows: Gene Expression Omnibus (GEO) Database stores public array‐ and sequence‐based functional genomics data, which allows users' query and downloading of experiments and gene expression profiles [11](#feb412198-bib-0011){ref-type="ref"}. Meanwhile, The Cancer Genome Atlas (TCGA) is one prominent example of the renowned public databases which contains the genetic information of various cancers. Furthermore, natural language processing (NLP) is a booming technique which teaches computers to comprehend and to sort out natural language by algorithms and programs, enabling researchers to retrieve papers on certain topics of interest and to analyze data automatically [12](#feb412198-bib-0012){ref-type="ref"}.

A succession of resources and techniques in bioinformatics and computational biology were applied in the study, which includes GEO and TCGA data aggregation, comprehensive meta‐analyses, NLP analysis, target genes prediction, analytic integration, and bioinformatics analyses. We aimed to validate the down‐regulation of miR‐146a‐5p in HCC with the most complete data currently available and to present the audience with the intriguing gene signatures, regulatory pathways, and networks of miR‐146a‐5p in the carcinogenesis, metastasis, prognosis, recurrence, survival, and drug‐resistance (sorafenib and bevacizumab) of HCC.

Materials and methods {#feb412198-sec-0002}
=====================

The present study consists of several processes sequentially (Fig. [1](#feb412198-fig-0001){ref-type="fig"}), that is, GEO‐based clinical values verification, TCGA‐based RNA‐seq data aggregation, comprehensive meta‐analyses based on GEO, TCGA and literature data, and multiple bioinformatics analyses.

![General flow chart. The present study is composed of several procedures sequentially; that is, GEO‐based verification of clinical values, TCGA‐based data aggregation of RNA‐seq, comprehensive meta‐analyses, and multiple bioinformatics analyses.](FEB4-7-504-g001){#feb412198-fig-0001}

Clinical value verification of miR‐146a‐5p expression in HCC based on GEO datasets {#feb412198-sec-0003}
----------------------------------------------------------------------------------

All the functional genomics data of miR‐146a‐5p were requested and assembled from the GEO Database (<http://www.ncbi.nlm.nih.gov/geo/>) with the closing date of 10 September 2016. The search strategy formulated in the GEO datasets (<http://www.ncbi.nlm.nih.gov/gds/>) was as follows: (malignan\* OR cancer OR tumor OR tumour OR neoplas\* OR carcinoma) AND (hepatocellular OR liver OR hepatic OR HCC). Inclusion criteria were listed below: (a) HCC tissues were included in each dataset with each group containing more than two samples, regardless of the inclusion of adjacent noncancerous tissues (or healthy liver tissues); (b) the dataset sample organism was Homo sapiens; (c) the expression data of miR‐146a (hsa‐miR‐146a or hsa‐miR‐146a‐5p) from the experimental and control groups could be provided or calculated. Meanwhile, the following conditions might cause the exclusion of related datasets: (a) datasets without information on miR‐146a‐5p; (b) datasets without complete data for analysis; (c) samples based on cell lines; (d) not all the subjects of the included studies were human; or (e) miR‐146a‐5p was determined in the HCC patients without a comparison. Expression values of miR‐146a‐5p and sample size in both test and control groups were calculated. Moreover, means and standard deviations of these values were extracted to estimate the different levels of miR‐146a‐5p in case and control groups by using Review Manager 5.3 with random‐effects model. The chi‐square test and the *I* ^2^ statistics were applied to evaluate the heterogeneity across studies. It was considered to be heterogeneous when the *P* value \<0.05 or *I* ^2^ \> 50%. Furthermore, SMD and its 95% CI were pooled to assess the stability of the analysis. It was considered to be statistically significant if the corresponding 95% CI for the pooled SMD did not overlap 1 or ‐1. Additionally, sensitivity analysis was conducted by eliminating each study to evaluate the source of heterogeneity.

RNA‐seq data aggregation based on TCGA database {#feb412198-sec-0004}
-----------------------------------------------

From the TCGA (<http://cancergenome.nih.gov/>), we downloaded and extracted the data of miR‐146a‐5p expression from miRNASeqV2 (level 3), on 15 July 2016, through bulk download mode. MiR‐146a‐5p expression data were presented as upper quartile normalized Expectation‐Maximization (RSEM) count estimates [13](#feb412198-bib-0013){ref-type="ref"}, [14](#feb412198-bib-0014){ref-type="ref"} by using the 'rsem.gene.normalized_results' file type. Related data were processed without further transformation, except that some values were rounded off to integers. The expression data between HCC and adjacent normal liver tissues were compared by limma package in R. Fold changes (FCs) were calculated as HCC vs. normal liver tissue. It would be considered as statistically significant if a FC value was \<0.5 or \>2 and with the *P* value \<0.05 in Student\'s *t*‐test.

Comprehensive meta‐analysis based on GEO, TCGA, and literature data {#feb412198-sec-0005}
-------------------------------------------------------------------

Comprehensive meta‐analyses were performed based on the data gathered from GEO, TCGA, and relevant literature. Related studies were selected by comprehensively searching through the online databases PubMed, Embase, Web of Science, Wiley Online Library, Cochrane Library, Science Direct, Chinese WanFang Database, Chinese VIP Database, Chinese Biomedical Literature Database, and Chinese CNKI Database up to 15 July 2016, independently. The following combination of keywords and entry words was employed: (a) (miR‐146a OR miRNA‐146a OR microRNA‐146a OR miR146a OR miRNA146a OR microRNA146a OR 'miR 146a' OR 'miRNA 146a' OR 'microRNA 146a\'OR miR‐146a‐5p OR miRNA‐146a‐5p OR microRNA‐146a‐5p); (b) (hepatocellular OR liver OR hepatic OR HCC); (c) ('cancer' OR 'tumor' OR 'tumour' OR 'neoplas\*' OR 'carcinoma' OR 'sarcoma' OR 'malignan\*'). In addition, some references of relevant articles were manually searched for further studies. Whichever articles fulfilled all the following criteria were considered to be included: (a) There was no language restriction of the publications. (b) Patients with HCC were included. (c) The difference of miR‐146a‐5p expression between HCC and noncancerous controls was estimated. (d) If the study of the same patient cohort was published twice or more, only the most complete and recently published one would be included. Listed below were situations which caused the exclusion of related articles: (a) Reviews, letters, comments, case reports, editorials, expert opinions, and conference abstracts without original data were excluded. (b) Articles of experimental *in vitro* or *in vivo* studies were excluded. (c) We also excluded the studies with no information on the difference of miR‐146a‐5p between HCC and controls. (d) Since we had downloaded and evaluated TCGA data by ourselves, those studies based on TCGA data were excluded for the meta‐analysis based on literature.

The statistics were analyzed using [spss]{.smallcaps} 22.0 software (Armonk, NY, USA). The final data after calculation were presented as the means ± SD. Student\'s *t*‐test was used for a comparative analysis of two independent groups. To differentiate the expression data between controls and HCC tissues, the diagnostic value was identified using a receiver operator characteristic (ROC) curve. Any *P* value \<0.05 denoted statistical significance. The meta‐analysis was performed using [revman]{.smallcaps} 5.3 (London, UK) 5.3. A standard mean difference (SMD) and a 95% confidence interval (CI) were utilized to measure continuous outcomes. Fixed or random‐effects models were applied to pool the effect sizes. Cochrane\'s *Q* test (Chi‐square test; Chi^2^) and inconsistency (*I*²) test were conducted to assess heterogeneity. A *P* \< 0.05 or *I*² \> 50% indicated significant heterogeneity, and a random‐effects model was applied. Otherwise, the fixed effects model would be selected. A funnel plot was generated to evaluate publication bias. A *P* value \<0.05 was considered to indicate statistical significance.

Bioinformatics analyses of miR‐146a‐5p and HCC {#feb412198-sec-0006}
----------------------------------------------

Generally, the bioinformatics analyses were conducted as formerly described [15](#feb412198-bib-0015){ref-type="ref"}, which included NLP procedure of HCC, prediction of miR‐146a‐5p target genes, and comprehensive analyses of the integrated genes.

### NLP procedure of HCC {#feb412198-sec-0007}

First of all, we conducted the document mining in PubMed, which included all related articles published between 1 January 1980 and 25 May 2015. The combination of keywords used was as listed: (hepatocellular carcinoma) AND (resistance OR prognosis OR metastasis OR recurrence OR survival OR carcinogenesis OR sorafenib OR bevacizumab) and ('1980/01/01' \[PDAT\]: '2015/05/25' \[PDAT\]). A detailed list of relevant proteins and genes was created afterwards. Later on, obtained data went through multiple processes; that is, gene mention tagging and conjunction resolution by ABNER (<http://pages.cs.wisc.edu/~bsettles/abner/>) as well as gene name normalization according to Entrez Database developed by NCBI [16](#feb412198-bib-0016){ref-type="ref"}, [17](#feb412198-bib-0017){ref-type="ref"}. Finally came the statistical analysis featured by the hypergeometric distribution formulae shown, that is, $p = 1 - {\sum_{i = 0}^{k - 1}p{(i|n,m,N)}}$ and $p(i|n,m,N) = ({{n!(N - n)!m!(N - m)!})/({(n - i)!i!(n - m)!(N - n - m + i)!N!}})$. *N* was defined as the total number of articles in PubMed. The letters *m* and *n* stood for the occurrence frequencies of relevant genes and HCC in PubMed, respectively. *K* was denoted as the co‐occurrence frequency of a certain gene and HCC at the same time in actual cases. Thus, we could calculate the probability of cocitation occurrence frequency greater than *k* under completely randomized conditions. The frequency of occurrence was output for each gene respectively: the higher frequency a certain gene demonstrated, the greater opportunity the gene harbored to be HCC‐related. The above methods for NLP procedure and corresponding results for HCC have been reported in our previous research article [15](#feb412198-bib-0015){ref-type="ref"}.

### Prediction of miR‐146a‐5p target genes {#feb412198-sec-0008}

A combination of 11 gene prediction platforms were used to predict the potential miR‐146a‐5p target genes; that is, TargetScan/TargetScanS [18](#feb412198-bib-0018){ref-type="ref"}, MirTarget2 [19](#feb412198-bib-0019){ref-type="ref"}, DIANA‐microT [20](#feb412198-bib-0020){ref-type="ref"}, PicTar [21](#feb412198-bib-0021){ref-type="ref"}, PITA [22](#feb412198-bib-0022){ref-type="ref"}, MicroInspector [23](#feb412198-bib-0023){ref-type="ref"}, miRanda [24](#feb412198-bib-0024){ref-type="ref"}, RNA22 [25](#feb412198-bib-0025){ref-type="ref"}, miTarget [26](#feb412198-bib-0026){ref-type="ref"}, RNAhybrid [27](#feb412198-bib-0027){ref-type="ref"}, and NBmiRTar [28](#feb412198-bib-0028){ref-type="ref"}. A predicted target gene would only be considered when nominated by at least four gene prediction platforms.

### Comprehensive integration {#feb412198-sec-0009}

We comprehensively analyzed HCC‐related genes from NLP procedure and potential miR‐146a‐5p target genes from prediction platforms and later generated the integration of the corresponding overlaps.

### Enrichment pathway {#feb412198-sec-0010}

We both mapped relevant genes into the Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Database and calculated the enrichment *P* values of each pathway using [genmapp]{.smallcaps} v2.1 [29](#feb412198-bib-0029){ref-type="ref"}.

### Gene connectivity {#feb412198-sec-0011}

The gene connectivity was calculated as a quantitative index to demonstrate the degree of interactions among genes and proteins.

### Regulatory network {#feb412198-sec-0012}

There were three different types of interaction relationships to construct the regulatory networks: (a) Available data from KEGG Database: we achieved the relevant data from KEGG Pathway Database and ported them into R (<https://www.r-project.org/>) with the [keggsoap]{.smallcaps} package (<http://www.bioconductor.org/packages/2.4/bioc/html/KEGGSOAP.html>) undergoing a genome‐wide interaction analysis (enzyme--enzyme relation, protein--protein interaction, and gene expression interaction). (b) Data from high‐throughput experiments: the MIPS Mammalian Protein--Protein Interaction Database (<http://mips.helmholtz-muenchen.de/proj/ppi/>) were employed for the protein--protein interactions data. (c) Existing data regarding gene interactions: data were processed with the hypergeometric distribution algorithm.

All the above factors and data were analyzed comprehensively and visualized by the [medusa]{.smallcaps} software (Cambridge, UK) in form of networks.

Results {#feb412198-sec-0013}
=======

GEO dataset verification of down‐regulated miR‐146a‐5p expression in HCC {#feb412198-sec-0014}
------------------------------------------------------------------------

A total of 2705 microarrays were identified during the primary searching, among which 22 were later downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) after relevant assessments and evaluation. Eventually, nine microarrays were included in this part ([GSE69580](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69580), [GSE54751](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54751), [GSE41874](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41874), [GSE40744](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40744), [GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362), [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058), [GSE12717](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12717), [GSE57555](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57555), and [GSE10694](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10694), Fig. [2](#feb412198-fig-0002){ref-type="fig"}) after screening and inspection in accordance with the aforementioned inclusion criteria. Three microarrays ([GSE41874](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41874), [GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362), and [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058)) demonstrated that the miR‐146a‐5p expression was significantly lower in HCC tissues than that in noncancerous tissues. Two microarrays ([GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362) and [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058)) (Fig. [3](#feb412198-fig-0003){ref-type="fig"}) displayed the significant diagnostic value of miR‐146a‐5p in HCC (AUC = 0.749, 95% CI: 0.669--0.830, *P* \< 0.001; AUC = 0.801, 95% CI: 0.731--0.872, *P* \< 0.001, respectively). The detailed information of the included studies for the meta‐analysis was summarized in Table [1](#feb412198-tbl-0001){ref-type="table-wrap"} and the flowchart of this meta‐analysis was shown in Fig. [4](#feb412198-fig-0004){ref-type="fig"}. In short, 319 HCC and 315 nontumor liver tissues in GEO database were included for the later meta‐analysis. The pooled SMD of miR‐146a‐5p was −0.470 (95% CI: −0.902 to −0.038), *P* = 0.033, Fig. [5](#feb412198-fig-0005){ref-type="fig"}A) by the random‐effects model and the *P* value of the heterogeneity test was \<0.001 (*I* ^2^ = 79%). The funnel plot shown in Fig. [5](#feb412198-fig-0005){ref-type="fig"}B did not imply significant publication bias (Begg\'s test: *P* = 0.917; Egger\'s test: *P* = 0.760).

![The expression data of miR‐146a‐5p in HCC in multiple microarrays from GEO. Nine microarrays were included in the analysis, among which three ([GSE41874](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41874), [GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362), [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058)) proved it to be statistically significant that the miR‐146a‐5p expression was decreased in HCC tissues as compared to noncancerous tissues.](FEB4-7-504-g002){#feb412198-fig-0002}

![The ROC curve of miR‐146a‐5p for HCC in two microarrays. Two microarrays ([GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362) and [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058)) demonstrated the significant diagnostic value of miR‐146a‐5p in HCC. (A) [GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362); AUC=0.749, 95% CI: 0.669--0.830, *P* \< 0.001. (B) [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058); AUC=0.801, 95% CI: 0.731--0.872, *P* \< 0.001.](FEB4-7-504-g003){#feb412198-fig-0003}

###### 

Summary of the included studies in the meta‐analysis

  Study                                                                    HCC (*n*)   MiR‐146a‐5p expression   Nontumor (*n*)   MiR‐146a‐5p expression   *t*       *P*               
  ------------------------------------------------------------------------ ----------- ------------------------ ---------------- ------------------------ --------- -------- -------- ---------
  [GSE69580](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69580)   5           9.8928                   13.2138          5                        3.4452    1.3785   1.085    0.309
  [GSE54751](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54751)   10          0.1380                   0.1312           10                       0.1882    0.1004   −0.959   0.35
  [GSE41874](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41874)   3           0.8520                   0.1265           3                        1.7150    0.2703   −5.008   0.007
  [GSE40744](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40744)   39          9.9121                   1.3010           18                       9.8072    0.4518   0.448    0.656
  [GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362)   73          6.4679                   1.5814           73                       7.5048    0.9066   −4.86    \<0.001
  [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058)   96          0.9892                   0.3288           96                       1.26766   0.1114   −7.858   \<0.001
  [GSE12717](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12717)   10          10.7535                  1.3380           6                        10.7052   0.3907   0.085    0.933
  [GSE57555](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57555)   5           −0.0419                  0.0056           16                       −0.0211   0.0253   −0.991   0.323
  [GSE10694](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10694)   78          11.0580                  0.5132           88                       11.1343   0.4773   −1.796   0.088
  Our combined data(2016)                                                  89          0.7302                   0.5142           89                       1.3015    0.6934   −7.911   \<0.001
  TCGA(2016)                                                               354         8.0304                   1.6810           50                       8.9665    0.8451   −6.274   \<0.001
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![The flow chart of the meta‐analysis. We included a union of 762 HCC and 454 nontumor liver tissues for the meta‐analysis, which is from GEO database, TCGA dataset, our previous research article, and newly added samples and stands for the most complete data available.](FEB4-7-504-g004){#feb412198-fig-0004}

![The forest plot and Begg\'s funnel plot of miR‐146a‐5p expression data in microarrays from GEO database. (A) The miR‐146a‐5p expression data of 319 HCC and 315 noncancerous liver tissues from GEO database were included. The pooled SMD of miR‐146a‐5p was −0.470 (95% CI:−0.902 to −0.038), *P* = 0.033) by the random‐effects model and the *P* value of the heterogeneity test was \<0.001 (*I* ^2^ = 79%). (B) No publication bias was observed in the funnel plot (Begg\'s test: *P* = 0.917; Egger\'s test: *P* = 0.760).](FEB4-7-504-g005){#feb412198-fig-0005}

TCGA RNA‐seq datasets {#feb412198-sec-0015}
---------------------

For the RNA‐seq data, 377 randomized HCC tissues and 50 normal tissues were retrieved from the TCGA database (<http://cancergenome.nih.gov/publications/publicationguidelines>). The non‐HCC samples or samples with data deficiency were excluded; and 354 HCC patients were finally included in this study. Besides, the data of 50 normal liver tissues were retrieved for comparison. The expression of miR‐146a‐5p in HCC was down‐regulated (8.0304 ± 1.6810), as compared to its expression in normal liver tissues (8.9665 ± 0.8451, *t* = −6.274, *P* \< 0.001, Fig. [6](#feb412198-fig-0006){ref-type="fig"}A). Moreover, a moderate diagnostic value of miR‐146a‐5p was identified via the receiver operator characteristic (ROC) curve and the area under the curve (AUC) was 0.686 (95% CI: 0.628--0.744, *P* \< 0.001, Fig. [6](#feb412198-fig-0006){ref-type="fig"}B).

![The miR‐146a‐5p expression data in HCC from TCGA datasets. (A) As for data gathered from the TCGA datasets, the miR‐146a‐5p expression in HCC was significantly decreased as compared to that in noncancerous liver tissues (8.0304 ± 1.6810 vs 8.9665 ± 0.8451, *t* = −6.274, *P* \< 0.001). (B) The moderate diagnostic power of miR‐146a‐5p was identified from the receiver operator characteristic (ROC) curve based on TCGA data (AUC: 0.686, 95% CI: 0.628--0.744, *P* \< 0.001).](FEB4-7-504-g006){#feb412198-fig-0006}

Comprehensive meta‐analysis {#feb412198-sec-0016}
---------------------------

After the search of electronic literature records, only one paper [9](#feb412198-bib-0009){ref-type="ref"} formerly published by the current research group was found to be qualified according to the inclusion criteria. As previously reported [9](#feb412198-bib-0009){ref-type="ref"}, 85 HCC tissues with 85 corresponding adjacent nontumor liver tissues were investigated. In the current study, four new pairs of HCC and corresponding noncancerous tissues were included for the detection of miR‐146a‐5p expression with methods described previously [9](#feb412198-bib-0009){ref-type="ref"}. As can be expected, a lower level of miR‐146‐5p was observed in HCC tissues (0.7302 ± 0.5142) when compared with that in adjacent noncancerous liver tissues (1.3015 ± 0.6934, *t* = −7.911, *P* \< 0.001, Fig. [7](#feb412198-fig-0007){ref-type="fig"}A). The AUC of miR‐146a‐5p in ROC was 0.787 (95% CI: 0.720--0.854, *P* \< 0.001, Fig. [7](#feb412198-fig-0007){ref-type="fig"}B). The larger sample size of 89 tissue pairs was used for the following meta‐analysis.

![The miR‐146a‐5p expression data in HCC from qRT‐PCR. (A) The qRT‐PCR expression data, from our previous research with four newly added pairs, demonstrated that miR‐146a‐5p was significantly down‐regulated when compared to that in nontumor liver tissues (0.7302 ± 0.5142 vs 1.3015 ± 0.6934, *t* = −7.911, *P* \< 0.001). (B) The AUC of miR‐146a‐5p here in ROC was 0.787 (95% CI: 0.720--0.854, *P* \< 0.001).](FEB4-7-504-g007){#feb412198-fig-0007}

The combination of 762 HCC and 454 noncancerous liver tissues was included for the meta‐analysis, which was from the various recourses such as GEO database, TCGA dataset, the previous article [9](#feb412198-bib-0009){ref-type="ref"} and newly added samples and represents the most complete data available. The pooled SMD of miR‐146a‐5p was −0.554 (95% CI: −0.866 to −0.241), *P* = 0.001, Fig. [8](#feb412198-fig-0008){ref-type="fig"}A) by the random‐effects model and the *P* value of the heterogeneity test was \<0.001 (*I* ^2^ = 76%). The funnel plot shown in Fig. [8](#feb412198-fig-0008){ref-type="fig"}B did not indicate publication bias (Begg\'s test: *P* = 0.876; Egger\'s test: *P* = 0.460). In summary, the current meta‐analysis further confirmed the down‐regulation of miR‐146a‐5p in HCC.

![The forest plot and Begg\'s funnel plot of miR‐146a‐5p expression data from the most complete combination available of GEO database, TCGA dataset, our previous research article and four newly added pairs. (A) The miR‐146a‐5p expression data of 762 HCC and 454 noncancerous liver tissues from multiple resources were included. The pooled SMD of miR‐146a‐5p was −0.554 (95% CI: −0.866 to −0.241), *P* = 0.001) by the random‐effects model and the *P* value of the heterogeneity test was \<0.001 (*I* ^2^ = 76%). (B) No publication bias was observed in the funnel plot (Begg\'s test: *P* = 0.876; Egger\'s test: *P* = 0.460).](FEB4-7-504-g008){#feb412198-fig-0008}

Gene signatures of miR‐146a‐5p and HCC from the perspective of bioinformatics {#feb412198-sec-0017}
-----------------------------------------------------------------------------

### NLP procedure of HCC {#feb412198-sec-0018}

As formerly reported [15](#feb412198-bib-0015){ref-type="ref"}, a complete list of 64 577 entries of HCC‐related titles and abstracts was generated based on the literature from PubMed. The ensuing hypergeometric distribution algorithm featured 1800 HCC‐related genes [15](#feb412198-bib-0015){ref-type="ref"}.

### Prediction of miR‐146a‐5p target genes {#feb412198-sec-0019}

The prediction of miR‐146a‐5p target genes was performed with a union of 11 bioinformatics platforms as described. A certain gene would only be included if nominated by at least four prediction solutions. Accordingly, 251 genes were deemed eligible as potential miR‐146a‐5p target genes for the succeeding analyses.

### Comprehensive integration {#feb412198-sec-0020}

The comprehensive integration yielded a total of 104 genes (Table [2](#feb412198-tbl-0002){ref-type="table-wrap"}) by overlapping HCC‐related genes from NLP and miR‐146a‐5p potential target genes from prediction platforms.

###### 

The comprehensive integration generated a total of 104 genes by overlapping HCC‐related genes from NLP and miR‐146a‐5p potential target genes from prediction platforms

  Gene        *P* value    Gene description
  ----------- ------------ ----------------------------------------------------------------------------------------------------
  ABCA1       0.022421     ATP‐binding cassette, subfamily A (ABC1), member 1
  ABCC10      0.02059      ATP‐binding cassette, subfamily C (CFTR/MRP), member 10
  ABCC11      0.03274      ATP‐binding cassette, subfamily C (CFTR/MRP), member 11
  AFAP1L2     0.014458     Actin filament‐associated protein 1‐like 2
  ANG         0.00060774   Angiogenin, ribonuclease, RNase A family, 5
  APEX1       0.0010269    APEX nuclease (multifunctional DNA repair enzyme) 1
  ARAF        0.074089     v‐raf murine sarcoma 3611 viral oncogene homolog
  ATP7B       0.26196      ATPase, Cu++ transporting, beta polypeptide
  BMP7        0.00080754   Bone morphogenetic protein 7
  BNIP3       0.0047602    BCL2/adenovirus E1B 19 kDa interacting protein 3
  BRCA1       0.65001      Breast cancer 1, early onset
  BTG2        0.0035189    BTG family, member 2
  C1ORF43     0.014458     Chromosome 1 open reading frame 43
  CARD10      0.026684     Caspase recruitment domain family, member 10
  CCL3        0.033443     Chemokine (C‐C motif) ligand 3
  CCNA2       \<1.00E‐08   Cyclin A2
  CCNE2       0.00033179   Cyclin E2
  CCT3        0.036756     Chaperonin containing TCP1, subunit 3 (gamma)
  CD40LG      3.70E‐07     CD40 ligand
  CDKN3       0.03475      Cyclin‐dependent kinase inhibitor 3
  CFH         0.40925      Complement factor H
  CHD1L       \<1.00E‐08   Chromodomain helicase DNA‐binding protein 1‐like
  CHEK1       0.00042545   CHK1 checkpoint homolog (S. pombe)
  CHFR        0.076014     Checkpoint with forkhead and ring finger domains
  CKAP4       0.00080042   Cytoskeleton‐associated protein 4
  CNDP2       0.012405     CNDP dipeptidase 2 (metallopeptidase M20 family)
  COMMD7      0.012405     COMM domain containing 7
  COPS8       0.044739     COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis)
  CRY1        0.00097051   Cryptochrome 1 (photolyase‐like)
  CTTN        \<1.00E‐08   Cortactin
  CYP2E1      0.005351     Cytochrome P450, family 2, subfamily E, polypeptide 1
  DENND2D     0.010348     DENN/MADD domain containing 2D
  EGFR        \<1.00E‐08   Epidermal growth factor receptor (erythroblastic leukemia viral (v‐erb‐b) oncogene homolog, avian)
  EIF5A2      3.16E‐06     Eukaryotic translation initiation factor 5A2
  EPHA5       0.00097051   EPH receptor A5
  ERBB4       0.19289      v‐erb‐a erythroblastic leukemia viral oncogene homolog 4 (avian)
  FADD        \<1.00E‐08   Fas (TNFRSF6)‐associated via death domain
  FAS         2.16E‐08     Fas (TNF receptor superfamily, member 6)
  FBXO8       0.01855      F‐box protein 8
  FGB         0.35531      Fibrinogen beta chain
  GALNT10     0.012405     UDP‐N‐acetyl‐alpha‐D‐galactosamine:polypeptide N‐acetylgalactosaminyltransferase 10 (GalNAc‐T10)
  GNB2L1      0.0013975    Guanine nucleotide‐binding protein (G protein), beta polypeptide 2‐like 1
  GPX3        0.0021848    Glutathione peroxidase 3 (plasma)
  GTF2I       0.093154     General transcription factor II, i
  HAS2        0.048705     Hyaluronan synthase 2
  HNRNPD      0.11919      Heterogeneous nuclear ribonucleoprotein D (AU‐rich element RNA‐binding protein 1, 37 kDa)
  IFI6        0.028707     Interferon, alpha‐inducible protein 6
  IL3         0.13011      Interleukin 3 (colony‐stimulating factor, multiple)
  IRAK1       0.17076      Interleukin‐1 receptor‐associated kinase 1
  JMJD1A      0.016506     Jumonji domain containing 1A
  KIF18A      0.030725     Kinesin family member 18A
  KISS1       5.77E‐08     KiSS‐1 metastasis‐suppressor
  KRT23       0.02059      Keratin 23 (histone deacetylase inducible)
  LAMA2       0.076014     Laminin, alpha 2
  LCK         0.47203      Lymphocyte‐specific protein tyrosine kinase
  LIN28       \<1.00E‐08   lin‐28 homolog (*Caenorhabditis elegans*)
  LYZ         0.10626      Lysozyme (renal amyloidosis)
  MARK2       0.0025961    MAP/microtubule affinity‐regulating kinase 2
  MCPH1       0.054624     Microcephalin 1
  MMP11       2.83E‐05     Matrix metallopeptidase 11 (stromelysin 3)
  MST1R       0.093154     Macrophage‐stimulating 1 receptor (c‐met‐related tyrosine kinase)
  MTA2        0.056589     Metastasis‐associated 1 family, member 2
  MVD         0.01855      Mevalonate (diphospho) decarboxylase
  NFE2        0.046724     Nuclear factor (erythroid‐derived 2), 45 kDa
  NME1        \<1.00E‐08   Nonmetastatic cells 1, protein (NM23A) expressed in
  NODAL       0.042749     Nodal homolog (mouse)
  NOX4        0.0053453    NADPH oxidase 4
  NP          0.074089     Nucleoside phosphorylase
  PA2G4       7.75E‐05     Proliferation‐associated 2G4, 38 kDa
  PBLD        0.014458     Phenazine biosynthesis‐like protein domain containing
  PDGFRB      1.82E‐06     Platelet‐derived growth factor receptor, beta polypeptide
  PER3        3.49E‐05     Period homolog 3 (Drosophila)
  PFTK1       0.024657     PFTAIRE protein kinase 1
  PIWIL4      0.016506     piwi‐like 4 (Drosophila)
  PLAUR       \<1.00E‐08   Plasminogen activator, urokinase receptor
  PLK2        0.036756     Polo‐like kinase 2 (Drosophila)
  PMS1        0.0014645    PMS1 postmeiotic segregation increased 1 (*Saccharomyces cerevisiae*)
  PPP2R4      \<1.00E‐08   Protein phosphatase 2A activator, regulatory subunit 4
  PRDX4       0.00038652   Peroxiredoxin 4
  PSMD10      4.63E‐06     Proteasome (prosome, macropain) 26S subunit, non‐ATPase, 10
  RAC2        0.0053453    ras‐related C3 botulinum toxin substrate 2 (rho family, small GTP‐binding protein Rac2)
  ROCK1       3.31E‐07     Rho‐associated, coiled‐coil containing protein kinase 1
  SLC1A5      0.052655     Solute carrier family 1 (neutral amino acid transporter), member 5
  SMAD4       \<1.00E‐08   SMAD family member 4
  SNRPE       6.08E‐05     Small nuclear ribonucleoprotein polypeptide E
  SORT1       0.077934     Sortilin 1
  TFF3        0.0047602    Trefoil factor 3 (intestinal)
  TGIF1       0.076014     TGFB‐induced factor homeobox 1
  TLR3        4.45E‐07     Toll‐like receptor 3
  TNFRSF13B   7.17E‐05     Tumor necrosis factor receptor superfamily, member 13B
  TPT1        0.0035189    Tumor protein, translationally controlled 1
  TRAF2       0.046769     TNF receptor‐associated factor 2
  TRAF6       0.037075     TNF receptor‐associated factor 6
  TRAV10      0.0020783    T‐cell receptor alpha variable 10
  TSPAN1      \<1.00E‐08   Tetraspanin 1
  UHRF1       0.052655     Ubiquitin‐like with PHD and ring finger domains 1
  VIM         \<1.00E‐08   Vimentin
  VWCE        6.44E‐05     von Willebrand factor C and EGF domains
  WASF2       0.07985      WAS protein family, member 2
  WNT3        0.00088342   Wingless‐type MMTV integration site family, member 3
  XPC         0.0035853    Xeroderma pigmentosum, complementation group C
  XRCC1       \<1.00E‐08   X‐ray repair complementing defective repair in Chinese hamster cells 1
  ZDHHC2      9.00E‐05     Zinc finger, DHHC‐type containing 2
  ZNF23       0.01855      Zinc finger protein 23 (KOX 16)

John Wiley & Sons, Ltd

### Pathway enrichment analysis {#feb412198-sec-0021}

Pathway enrichment analyses were performed for both miR‐146a‐5p predicted target genes and HCC‐related genes. For miR‐146a‐5p predicted target genes, a panel of 59 pathways (Table [3](#feb412198-tbl-0003){ref-type="table-wrap"}) was identified, among which four were deemed both statistically significant (*P* ≤ 0.05) and scientifically valuable, namely neurotrophin signaling pathway (count = 5; *P* = 0.000627; IRAK1, NRAS, RAC1, SORT1, TRAF6), adherens junction (count=4; *P* = 0.001949; RAC1, SMAD4, YES1, IQGAP1), VEGF signaling pathway (count=3; *P* = 0.025301; NRAS, PTGS2, RAC1), and toll‐like receptor (TLR) signaling pathway (count = 3; *P* = 0.043766; IRAK1, RAC1, TRAF6). As to HCC‐related genes obtained from NLP procedure, 24 statistically significant pathways (*P* ≤ 0.05) were reported previously [15](#feb412198-bib-0015){ref-type="ref"}.

###### 

A panel of 59 pathways was identified for miR‐146a‐5p predicted target genes

  Term                                                                   Count   *P* value   Genes
  ---------------------------------------------------------------------- ------- ----------- ---------------------------------
  hsa04722: Neurotrophin signaling pathway                               5       6.27E‐04    IRAK1, NRAS, RAC1, SORT1, TRAF6
  hsa04520: Adherens junction                                            4       0.001949    RAC1, SMAD4, YES1, IQGAP1
  hsa05200: Pathways in cancer                                           5       0.020692    NRAS, PTGS2, RAC1, SMAD4, TRAF6
  hsa04370: VEGF signaling pathway                                       3       0.025301    NRAS, PTGS2, RAC1
  hsa04620: Toll‐like receptor signaling pathway                         3       0.043766    IRAK1, RAC1, TRAF6
  hsa04360: Axon guidance                                                3       0.067759    NRAS, ROBO1, RAC1
  hsa04810: Regulation of actin cytoskeleton                             3       0.159939    NRAS, RAC1, IQGAP1
  hsa05211: Renal cell carcinoma                                         2       0.210236    NRAS, RAC1
  hsa05212: Pancreatic cancer                                            2       0.215582    RAC1, SMAD4
  hsa04662: B cell receptor signaling pathway                            2       0.223537    NRAS, RAC1
  hsa05220: Chronic myeloid leukemia                                     2       0.223537    NRAS, SMAD4
  hsa04010: MAPK signaling pathway                                       3       0.223547    NRAS, RAC1, TRAF6
  hsa04664: Fc epsilon RI signaling pathway                              2       0.231416    NRAS, RAC1
  hsa05210: Colorectal cancer                                            2       0.246948    RAC1, SMAD4
  hsa05222: Small cell lung cancer                                       2       0.246948    PTGS2, TRAF6
  hsa04012: ErbB signaling pathway                                       2       0.254603    NRAS, ERBB4
  hsa04650: Natural killer cell mediated cytotoxicity                    2       0.363187    NRAS, RAC1
  hsa04530: Tight junction                                               2       0.365373    NRAS, YES1
  hsa04120: Ubiquitin‐mediated proteolysis                               2       0.371889    PARK2, TRAF6
  hsa04310: Wnt signaling pathway                                        2       0.401474    RAC1, SMAD4
  hsa04144: Endocytosis                                                  2       0.466104    ERBB4, TRAF6
  hsa04062: Chemokine signaling pathway                                  2       0.471642    NRAS, RAC1
  hsa04510: Focal adhesion                                               2       0.496777    TLN2, RAC1
  hsa00270: Cysteine and methionine metabolism                           1       \>0.99      MTAP
  hsa00590: Arachidonic acid metabolism                                  1       \>0.99      PTGS2
  hsa04020: Calcium signaling pathway                                    1       \>0.99      ERBB4
  hsa04060: Cytokine‐cytokine receptor interaction                       1       \>0.99      IL17A
  hsa04110: Cell cycle                                                   1       \>0.99      SMAD4
  hsa04142: Lysosome                                                     1       \>0.99      SORT1
  hsa04210: Apoptosis                                                    1       \>0.99      IRAK1
  hsa04320: Dorso‐ventral axis formation                                 1       \>0.99      NOTCH2
  hsa04330: Notch signaling pathway                                      1       \>0.99      NOTCH2
  hsa04350: TGF‐beta signaling pathway                                   1       \>0.99      SMAD4
  hsa04540: Gap junction                                                 1       \>0.99      NRAS
  hsa04610: Complement and coagulation cascades                          1       \>0.99      CFH
  hsa04621: NOD‐like receptor signaling pathway                          1       \>0.99      TRAF6
  hsa04622: RIG‐I‐like receptor signaling pathway                        1       \>0.99      TRAF6
  hsa04660: T‐cell receptor signaling pathway                            1       \>0.99      NRAS
  hsa04666: Fc gamma R‐mediated phagocytosis                             1       \>0.99      RAC1
  hsa04670: Leukocyte transendothelial migration                         1       \>0.99      RAC1
  hsa04710: Circadian rhythm                                             1       \>0.99      PER1
  hsa04720: Long‐term potentiation                                       1       \>0.99      NRAS
  hsa04730: Long‐term depression                                         1       \>0.99      NRAS
  hsa04910: Insulin signaling pathway                                    1       \>0.99      NRAS
  hsa04912: GnRH signaling pathway                                       1       \>0.99      NRAS
  hsa04916: Melanogenesis                                                1       \>0.99      NRAS
  hsa05012: Parkinson\'s disease                                         1       \>0.99      PARK2
  hsa05014: Amyotrophic lateral sclerosis (ALS)                          1       \>0.99      RAC1
  hsa05120: Epithelial cell signaling in Helicobacter pylori infection   1       \>0.99      RAC1
  hsa05213: Endometrial cancer                                           1       \>0.99      NRAS
  hsa05214: Glioma                                                       1       \>0.99      NRAS
  hsa05215: Prostate cancer                                              1       \>0.99      NRAS
  hsa05216: Thyroid cancer                                               1       \>0.99      NRAS
  hsa05218: Melanoma                                                     1       \>0.99      NRAS
  hsa05219: Bladder cancer                                               1       \>0.99      NRAS
  hsa05221: Acute myeloid leukemia                                       1       \>0.99      NRAS
  hsa05223: Nonsmall cell lung cancer                                    1       \>0.99      NRAS
  hsa05416: Viral myocarditis                                            1       \>0.99      RAC1
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### Gene connectivity {#feb412198-sec-0022}

The gene connectivity analysis provided us with a quantitative interface to understand the interacting degree of related genes and proteins. As to miR‐146a‐5p predicted target genes, the gene connectivity of RAC1 ranked top (*z*‐test, *P* = 0.007305, Fig. [9](#feb412198-fig-0009){ref-type="fig"}, Table [4](#feb412198-tbl-0004){ref-type="table-wrap"}) among all the 20 hub genes of miR‐146a‐5p, interacting with 10 different genes in total (ERBB4, IQGAP1, NRAS, PARK2, PTGS2, RACGAP1, ROBO1, SMAD4, TRAF6, YES1). For HCC‐related genes, the gene connectivity results were reported in our previous article [15](#feb412198-bib-0015){ref-type="ref"}.

![Gene connectivity test for miR‐146a‐5p predicted target genes. Gene connectivity test established the top gene connectivity of RAC1 (*z*‐test, *P* = 0.007305) among all the 20 hub genes of miR‐146a, interacting with 10 different genes in total.](FEB4-7-504-g009){#feb412198-fig-0009}

###### 

Results of gene connectivity test for miR‐146a‐5p predicted target genes

  Gene      Degrees   *P* value   Interactions
  --------- --------- ----------- -----------------------------------------------------------------------
  RAC1      10        0.007305    ERBB4, IQGAP1, NRAS, PARK2, PTGS2, RACGAP1, ROBO1, SMAD4, TRAF6, YES1
  NRAS      8         0.044385    ELAVL1, ERBB4, NOTCH2, PTGS2, RAC1, RACGAP1, SMAD4, YES1
  TRAF6     7         0.091440    ERBB4, IL17A, IRAK1, OTUD7B, PARK2, RAC1, SORT1
  ERBB4     5         0.276934    NOTCH2, NRAS, PTGS2, RAC1, TRAF6
  NOTCH2    5         0.276934    ERBB4, HEYL, NRAS, PTGS2, SMAD4
  PTGS2     5         0.276934    ELAVL1, ERBB4, NOTCH2, NRAS, RAC1
  ELAVL1    4         0.412161    NOVA1, NRAS, PARK2, PTGS2
  PARK2     4         0.412161    ELAVL1, RAC1, SMAD4, TRAF6
  SMAD4     4         0.412161    NOTCH2, NRAS, PARK2, RAC1
  YES1      4         0.412161    NRAS, PTPRE, RAC1, RACGAP1
  RACGAP1   3         0.558826    NRAS, RAC1, YES1
  HEYL      1         0.812719    NOTCH2
  IL17A     1         0.812719    TRAF6
  IQGAP1    1         0.812719    RAC1
  IRAK1     1         0.812719    TRAF6
  NOVA1     1         0.812719    ELAVL1
  OTUD7B    1         0.812719    TRAF6
  PTPRE     1         0.812719    YES1
  ROBO1     1         0.812719    RAC1
  SORT1     1         0.812719    TRAF6
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### Regulatory network {#feb412198-sec-0023}

Regulatory networks were constructed for miR‐146a‐5p predicted target genes (Fig. [10](#feb412198-fig-0010){ref-type="fig"}), HCC‐related genes [15](#feb412198-bib-0015){ref-type="ref"}, and the overlapping genes (Fig. [11](#feb412198-fig-0011){ref-type="fig"}), respectively. With regard to the overlapping genes, which are considered to be both miR‐146a‐5p and HCC‐related, miR‐132 might interact with RAC1, PTGS2, and NRAS via VEGF signaling pathway and mediate biological processes with SMAD4, YES1, and IQGAP1 via adherens junction. SORT1 might be associated with miR‐146a‐5p via neurotrophin signaling pathway and TLR signaling pathway could be in charge for the interactions and regulations between miR‐146a‐5p and TRAF6 and IRAK1. The rest of genes might interact with miR‐146a‐5p via various pathways.

![Regulatory network construction for miR‐146a‐5p predicted target genes. Regulatory network was constructed to unveil the potential regulatory network of miR‐146a‐5p.](FEB4-7-504-g010){#feb412198-fig-0010}

![Regulatory network construction for the overlapped genes. miR‐146a‐5p might interact with RAC1, PTGS2, and NRAS via VEGF signaling pathway and mediate biological processes with SMAD4, YES1 and IQGAP1 via adherens junction. SORT1 might be associated with miR‐146a‐5p via neurotrophin signaling pathway and Toll‐like receptor signaling pathway could be in charge for the interactions and regulations between miR‐146a and TRAF6 and IRAK1. The rest of genes might interact with miR‐146a‐5p via various pathways.](FEB4-7-504-g011){#feb412198-fig-0011}

Discussion {#feb412198-sec-0024}
==========

Hepatocellular carcinoma takes the third place for cancer‐related deaths and is the fifth most frequent type of cancer internationally [1](#feb412198-bib-0001){ref-type="ref"}, [2](#feb412198-bib-0002){ref-type="ref"}. To make things worse, delayed diagnosis, recurrence, and metastasis shatter the treatment opportunities for HCC patients [3](#feb412198-bib-0003){ref-type="ref"}. miRs are considered to be actively involved in numerous oncological processes [4](#feb412198-bib-0004){ref-type="ref"}, [5](#feb412198-bib-0005){ref-type="ref"}, and the conspicuous miR‐146a‐5p [6](#feb412198-bib-0006){ref-type="ref"}, [7](#feb412198-bib-0007){ref-type="ref"}, [8](#feb412198-bib-0008){ref-type="ref"} is one of them.

It has been reported in our previous article [9](#feb412198-bib-0009){ref-type="ref"} that miR‐146a‐5p is decreased and might play a tumor‐suppressive role in HCC. However, we believed that it would be of great merit to validate the down‐expression of miR‐146a‐5p in HCC with a larger cohort and that the potential molecular mechanisms and regulatory networks should be unveiled, which led to the current study.

In the present study, we took great advantage of the GEO and TCGA databases to gather massive data of miR‐146a‐5p expression in HCC and later performed a meta‐analysis with the GEO‐based microarrays, TCGA‐based RNA‐seq data, previous research [9](#feb412198-bib-0009){ref-type="ref"}, and four newly added tissue pairs in order to validate the miR‐146a‐5p down‐expression and to explore its diagnostic values in HCC. Furthermore, miR‐146a‐5p potential target genes were predicted on 11 bioinformatics solutions. With the formerly reported HCC‐related genes from NLP, we were able to develop the HCC‐ and miR‐146a‐5p‐related overlaps analytically. Last but not least, comprehensive analyses were conducted for the above genes in an attempt to discover the gene signatures and potential regulatory pathways and networks of miR‐146a‐5p in HCC.

In relation to the data acquisition, we employed the collaboration of GEO, TCGA, and reported qRT‐PCR as well as newly included pairs. In GEO Database, we included nine microarrays with 319 HCC and 315 noncancerous liver tissues ([GSE69580](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69580), [GSE54751](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54751), [GSE41874](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41874), [GSE40744](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40744), [GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362), [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058), [GSE12717](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12717), [GSE57555](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57555), and [GSE10694](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10694)) after rigorous screening procedures. Three microarrays ([GSE41874](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41874), [GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362), and [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058)) presented statistically significant results that the miR‐146a‐5p expression was decreased in HCC tissues as compared to the noncancerous counterparts. Two microarrays ([GSE21362](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21362) and [GSE22058](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058)) demonstrated the significant diagnostic value of miR‐146a‐5p in HCC (AUC = 0.749, 95% CI: 0.669--0.830, *P* \< 0.001; AUC = 0.801, 95% CI: 0.731--0.872, *P* \< 0.001, respectively). Meanwhile, in TCGA Database, the RNA‐seq data of 354 randomized HCC and 50 normal tissues were finally included. The miR‐146a‐5p expression in HCC was significantly down‐regulated as compared to its expression in normal liver tissues (8.0304 ± 1.6810 vs 8.9665 ± 0.8451, *t* = −6.274, *P* \< 0.001). Furthermore, a moderate diagnostic value of miR‐146a‐5p in HCC was perceived via ROC (AUC: 0.686; 95% CI: 0.628--0.744, *P* \< 0.001). Besides, a new combined cohort using qRT‐PCR was established by pooling data from the previous research [9](#feb412198-bib-0009){ref-type="ref"} and four newly included pairs. Unsurprisingly, the decreased expression of miR‐146‐5p was observed in HCC tissues (0.7302 ± 0.5142) when compared with that in adjacent noncancerous liver tissues (1.3015 ± 0.6934, *t* = −7.911, *P* \< 0.001) and the remarkable diagnostic value of miR‐146a‐5p in HCC should be denoted (AUC: 0.787; 95% CI: 0.720--0.854, *P* \< 0.001).

For the comprehensive meta‐analysis, a large cohort of 762 HCC and 454 noncancerous liver tissues from GEO database, TCGA dataset, the previous article, [9](#feb412198-bib-0009){ref-type="ref"} and four newly added samples were included, which renders the integrated perspective with the most complete data. A pooled SMD of −0.554 (95% CI: −0.866 to −0.241), *P* = 0.001) was presented by the random‐effects model. The *P* value of the heterogeneity test was \<0.001 (*I* ^2^ = 76%) and no publication bias was observed (Begg\'s test: *P* = 0.876; Egger\'s test: *P* = 0.460). Based on the above in the meta‐analysis, we can safely reach the conclusion that miR‐146a‐5p is down‐regulated in HCC, which is consistent with our previous findings [9](#feb412198-bib-0009){ref-type="ref"}.

The integrated computation consists of three parts; the natural language processing, the miR‐146a‐5p target genes' prediction, and the comprehensive integration of overlapped genes. The NLP [15](#feb412198-bib-0015){ref-type="ref"} established a record of 64 577 entries on the basis of the literature from PubMed, 1800 of which were proved HCC related by hypergeometric distribution. As to miR‐146a‐5p target genes' prediction, an unprecedented union of 11 prediction tools was employed, and 251 genes were considered to be potential miR‐146a‐5p target genes since they were nominated by at least four platforms. Eventually, the comprehensive integration yielded a total of 104 genes by overlapping results from NLP and gene prediction, which were deemed both HCC‐ and miR‐146a‐5p related.

Three comprehensive bioinformatics analyses were applied in the study; pathway enrichment test, gene connectivity test, and regulatory network construction. First of all, four pathways were highlighted among all the 59 pathways identified in the pathway enrichment analysis for miR‐146a‐5p predicted target genes; that is, neurotrophin signaling pathway (count = 5; *P* = 0.000627; IRAK1, NRAS, RAC1, SORT1, TRAF6), adherens junction (count = 4; *P* = 0.001949; RAC1, SMAD4, YES1, IQGAP1), VEGF signaling pathway (count = 3; *P* = 0.025301; NRAS, PTGS2, RAC1), and TLR signaling pathway (count = 3; *P* = 0.043766; IRAK1, RAC1, TRAF6). In the connectivity test for miR‐146a‐5p, RAC1 ranked top as the most interacted gene among all the 20 hub genes of miR‐146a‐5p (z‐test, *P* = 0.007305), interplaying with 10 other genes altogether (*ERBB4, IQGAP1, NRAS, PARK2, PTGS2, RACGAP1,ROBO1, SMAD4, TRAF6*, and *YES1*). Regulatory networks constructed for the overlapping genes demonstrated that miR‐132 in HCC might interact with RAC1, PTGS2, and NRAS via VEGF signaling pathway, mediate biological processes with SMAD4, YES1, and IQGAP1 via adherens junction, associate with TRAF6 and IRAK1 via TLR signaling pathway, and interplay with SORT1 via neurotrophin signaling pathway.

The gene with top connectivity for miR‐146a‐5p, RAC1, and four pathways with high enrichment for the overlapped genes are worthy of extra attention since they might provide unique insights into molecule‐based diagnostic and therapeutic strategies.

The RAC1 gene encodes the Rac1 protein, which has been reported to be significantly regulatory in cell growth and motility specifically [30](#feb412198-bib-0030){ref-type="ref"} and might result in metastasis, invasion [31](#feb412198-bib-0031){ref-type="ref"}, and epithelial mesenchymal transition (EMT) [32](#feb412198-bib-0032){ref-type="ref"} in the oncological context. In HCC, the up‐regulation of Tiam1 and Rac1 has been found to associate with poor prognosis [33](#feb412198-bib-0033){ref-type="ref"}. Our previous research showed that miR‐146a‐5p expression was related to clinical TNM stage and metastasis [9](#feb412198-bib-0009){ref-type="ref"}. The relations between other miRs and RAC1 gene in HCC have already been extensively studied. Zhou *et al*. [34](#feb412198-bib-0034){ref-type="ref"} reported that miR‐100 suppresses HCC metastasis by abolishing the ICMT‐Rac1 signaling and that the decrease in miR‐100 might promote the metastasis in HCC. Also, miR‐142‐3p is found to play a directly negative regulatory role of human RAC1 and able to suppress the HCC cell migration and invasion [35](#feb412198-bib-0035){ref-type="ref"}. The two studies [34](#feb412198-bib-0034){ref-type="ref"}, [35](#feb412198-bib-0035){ref-type="ref"} mutually complement and support our current and previous [9](#feb412198-bib-0009){ref-type="ref"} research in a sense: for one thing, the top connectivity highlighted the possible role of RAC1 in the down‐regulation of miR‐146a‐5p in HCC; for another, the two studies [34](#feb412198-bib-0034){ref-type="ref"}, [35](#feb412198-bib-0035){ref-type="ref"} established the validated role of RAC1 in miR‐related HCC and proved the vigorous validity of bioinformatics tools in the present research, rendering us the potential role of RAC1 in miR‐146a‐5p‐related HCC. Considering the above, we speculate that RAC1 might be negatively regulated by miR‐146a‐5p and promote metastasis in miR‐146a‐5p‐related HCC.

The VEGF signaling pathway is considered to play a significant role in vasculogenesis and angiogenesis [36](#feb412198-bib-0036){ref-type="ref"} by boosting the vascular permeability, proliferation and migration [37](#feb412198-bib-0037){ref-type="ref"}. The negative correlations [9](#feb412198-bib-0009){ref-type="ref"} between miR‐146a‐5p and portal vein tumor embolus as well as metastasis might be related to VEGF signaling pathway. Recent research [7](#feb412198-bib-0007){ref-type="ref"} proved that miR‐146a‐5p limits metastasis by down‐regulating VEGF in HCC, which supports our bioinformatics findings. Adherens junction is crucially associated with intercellular adhesion and is responsible for maintaining cell polarity and structures, which represses cell migration and proliferation [38](#feb412198-bib-0038){ref-type="ref"}. Thus, adherens junction might be positively regulated by miR‐146a‐5p and correlate with favorable clinical outcomes. TLR are widely expressed by various cells and play a significant part in inflammation and immune responses. Changes in TLR activities might exert the antitumor influence on HCC cells, which might prove useful for novel targeted therapeutics in HCC [39](#feb412198-bib-0039){ref-type="ref"}. Research has shown that the TLR pathway is involved in the initiation, progression, and metastasis of HCC and that the essential role of TLR4 should not be ignored in the pathogenesis and progression of HCC [40](#feb412198-bib-0040){ref-type="ref"}. Furthermore, studies [41](#feb412198-bib-0041){ref-type="ref"}, [42](#feb412198-bib-0042){ref-type="ref"}, [43](#feb412198-bib-0043){ref-type="ref"} have shown the involvement of TLR and TLR pathway in miR‐146a‐5p‐related HCC or other liver diseases, which illuminate the potential regulatory mechanisms of miR‐146a‐5p and TLR in HCC. Neurotrophin signaling pathway is thought to be actively involved in many biological processes in the nervous system, with the examples of neurocyte development and higher order behaviors such as learning and memory. Neurotrophin signaling pathway and related microRNAs mutually regulate each other and are considered highly related to multiple cancers and brain diseases, whose mechanisms are auspicious in developing novel diagnostic and therapeutic strategies [44](#feb412198-bib-0044){ref-type="ref"}. The network construction for the overlaps implied that SORT1 and miR‐146a‐5p might interact via the neurotrophin signaling pathway.

There are three articles by Zhou *et al*. [34](#feb412198-bib-0034){ref-type="ref"}, Wu *et al*. [35](#feb412198-bib-0035){ref-type="ref"}, and Zhang *et al*. [7](#feb412198-bib-0007){ref-type="ref"}, respectively, that are particularly noteworthy, since they prove the validity and feasibility of the current bioinformatics analyses to a certain extent. Zhou *et al*. [34](#feb412198-bib-0034){ref-type="ref"} stated that miR‐100 suppresses HCC metastasis by abolishing the ICMT‐Rac1 signaling and negatively correlates with metastasis in HCC, whereas Wu *et al*. argued that miR‐142‐3p negatively regulates RAC1 and is able to suppress the migration and invasion of HCC cells [35](#feb412198-bib-0035){ref-type="ref"}, both of which happened to cover the involvements of certain individual microRNAs in HCC and merit attention for the further verification of RAC1 and miR‐146a‐5p in HCC. Even more delightfully, Zhang *et al*. [7](#feb412198-bib-0007){ref-type="ref"} reported that miR‐146a‐5p confines metastasis by negatively regulating VEGF in HCC, which has precisely verified the bioinformatics discovery---the same microRNA (miR‐146a‐5p) exerts its influence in the same disease (HCC) via the exactly same identified pathway (VEGF signaling pathway).

Several aspects of the study add to its merits. First of all, the study gathered the most complete data currently available (762 HCC vs 454 noncancerous tissues) and validated the down‐regulation of miR‐146a‐5p in HCC, which is the first of its kind. Secondly, the study provided us with the gene signatures for HCC‐ and miR‐146a‐5p‐related overlapped genes, mapping out the potentially primary picture for the further exploration into the mechanisms. Thirdly, the powerful combination of 11 bioinformatics tools for prediction maximized the reliability of miR‐146a‐5p target gene prediction results, since other previous articles only used the utmost of three prediction platforms. Last but not least, the predicted target genes of miR‐146a‐5p and the related informatics analyses have all been made available in the current article along with the supplementary files, which are easily accessible and reusable for further study purposes. Still, *in vitro* experimental validation and verification are needed for the featured miR‐146a‐5p hub gene with top connectivity, RAC1, as well as the four identified pathways with their interacting genes, which the team plans to perform in future.

Conclusions {#feb412198-sec-0025}
===========

The study gathered the most complete data currently available from multiple resources (GEO‐based microarrays, TCGA‐based RNA‐seq data, and qRT‐PCR), validated the down‐regulation of miR‐146a‐5p and denoted its diagnostic values in HCC. An outstanding union of 11 bioinformatics platforms predicted a total of 251 potential target genes of miR‐146a‐5p. With the HCC‐related genes from NLP, the overlaps of 104 genes were generated, which are considered both HCC‐ and miR‐146a‐5p related. Last but not least, the bioinformatics analyses highlighted RAC1 as the most connected hub gene for miR‐146a‐5p and four pathways with high enrichment were featured for the overlapped genes, both of which could prove useful for future molecule‐based diagnostics and therapeutics of HCC.
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**Table S1.** List of all the 251 potential miR‐146a‐5p target genes. A total of 251 genes were predicted by at least four bioinformatics platforms, making them eligible potential miR‐146a‐5p target genes.
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Click here for additional data file.
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